Furthermore, elevated beta-2-microglobulin level (p = 0.47), plasmacytic differentiation (p = 0.92), paraproteinemia (p = 0.23), presence of an autoimmune disorder (p = 0.68) or IPI score>1 (p = 0.26) were not associated with a higher risk for relapse or progress after first line therapy. The gene discussed is B2M; the disease is autoimmune disease.